Comparative risk of incident cancer in ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study.
Auteur(s) :
Poullenot, Florian [Auteur]
Hôpital Haut-Lévêque [CHU Bordeaux]
Amiot, A. [Auteur]
CHU Henri Mondor [Créteil]
Nachury, Maria [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Viennot, S. [Auteur]
CHU Caen
Altwegg, R. [Auteur]
Hôpital Saint Eloi [CHRU Montpellier]
Bouhnik, Y. [Auteur]
Hôpital Beaujon [AP-HP]
Abitbol, V. [Auteur]
Hôpital Cochin [AP-HP]
Nancey, S. [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Vuitton, L. [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Peyrin-Biroulet, L. [Auteur]
Université de Lorraine [UL]
Biron, A. [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Fumery, Mathurin [Auteur]
Périnatalité et Risques Toxiques - UMR INERIS_I 1 [PERITOX]
Picon, L. [Auteur]
CHU Trousseau [APHP]
Vidon, M. [Auteur]
Reenaers, C. [Auteur]
Centre Hospitalier Universitaire de Liège [CHU-Liège]
Serrero, M. [Auteur]
Hôpital Nord [CHU - APHM]
Savoye, G. [Auteur]
CHU Rouen
Beaugerie, L. [Auteur]
CHU Saint-Antoine [AP-HP]
Rivière, P. [Auteur]
CHU Bordeaux
Laharie, D. [Auteur]
Hôpital Haut-Lévêque [CHU Bordeaux]
Hôpital Haut-Lévêque [CHU Bordeaux]
Amiot, A. [Auteur]
CHU Henri Mondor [Créteil]
Nachury, Maria [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Lille Inflammation Research International Center - U 995 [LIRIC]
Viennot, S. [Auteur]
CHU Caen
Altwegg, R. [Auteur]
Hôpital Saint Eloi [CHRU Montpellier]
Bouhnik, Y. [Auteur]
Hôpital Beaujon [AP-HP]
Abitbol, V. [Auteur]
Hôpital Cochin [AP-HP]
Nancey, S. [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Vuitton, L. [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Peyrin-Biroulet, L. [Auteur]
Université de Lorraine [UL]
Biron, A. [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Fumery, Mathurin [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Périnatalité et Risques Toxiques - UMR INERIS_I 1 [PERITOX]
Picon, L. [Auteur]
CHU Trousseau [APHP]
Vidon, M. [Auteur]
Reenaers, C. [Auteur]
Centre Hospitalier Universitaire de Liège [CHU-Liège]
Serrero, M. [Auteur]
Hôpital Nord [CHU - APHM]
Savoye, G. [Auteur]
CHU Rouen
Beaugerie, L. [Auteur]
CHU Saint-Antoine [AP-HP]
Rivière, P. [Auteur]
CHU Bordeaux
Laharie, D. [Auteur]
Hôpital Haut-Lévêque [CHU Bordeaux]
Titre de la revue :
Journal of Crohn's and Colitis
Nom court de la revue :
J Crohns Colitis
Numéro :
16
Pagination :
1523–1530
Date de publication :
2022-05-17
ISSN :
1876-4479
Mot(s)-clé(s) en anglais :
IBD
cancer
incident cancer
incident-cancer free survival
cancer
incident cancer
incident-cancer free survival
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Introduction
Knowledge about the cancer risk when initiating a biologic in inflammatory bowel disease [IBD] patients with prior malignancy remains scarce, especially for vedolizumab. Our aim was to evaluate the rate of ...
Lire la suite >Introduction Knowledge about the cancer risk when initiating a biologic in inflammatory bowel disease [IBD] patients with prior malignancy remains scarce, especially for vedolizumab. Our aim was to evaluate the rate of incident cancer in a cohort of IBD patients with prior non-digestive malignancy, according to the subsequent treatment given. Methods A multicentre retrospective study included consecutive IBD patients with prior non-digestive malignancy. Inclusion date corresponded to the diagnosis of index malignancy. Patients were categorized into different cohorts according to the first treatment [none, conventional immunosuppressant, anti-TNF, or vedolizumab] to which they were exposed after inclusion and before incident cancer [recurrent or new cancer]. Results Among the 538 patients {58% female; mean (standard deviation [SD]) age inclusion: 52 [15] years} analyzed, the most frequent malignancy was breast cancer [25%]. The first immunomodulator given after inclusion was a conventional immunosuppressant in 27% of patients, anti-TNF in 21%, or vedolizumab in 9%. With a median (interquartile range [IQR]) follow-up duration of 55 [23-100] months, 100 incident cancers were observed. Crude cancer incidence rates per 1000 person-years were 47.0 for patients receiving no immunomodulator, 36.6 in the anti-TNF cohort, and 33.6 in the vedolizumab cohort [p = 0.23]. Incident-cancer free survival rates were not different between patients receiving anti-TNF and those receiving vedolizumab [p = 0.56]. After adjustment, incidence rates were not different between patients receiving no immunomodulator, anti-TNF, or vedolizumab. Conclusions In this large multicentre cohort study, there was no difference of cancer incidence in those IBD patients with prior non-digestive malignancy, treated with vedolizumab or anti-TNF.Lire moins >
Lire la suite >Introduction Knowledge about the cancer risk when initiating a biologic in inflammatory bowel disease [IBD] patients with prior malignancy remains scarce, especially for vedolizumab. Our aim was to evaluate the rate of incident cancer in a cohort of IBD patients with prior non-digestive malignancy, according to the subsequent treatment given. Methods A multicentre retrospective study included consecutive IBD patients with prior non-digestive malignancy. Inclusion date corresponded to the diagnosis of index malignancy. Patients were categorized into different cohorts according to the first treatment [none, conventional immunosuppressant, anti-TNF, or vedolizumab] to which they were exposed after inclusion and before incident cancer [recurrent or new cancer]. Results Among the 538 patients {58% female; mean (standard deviation [SD]) age inclusion: 52 [15] years} analyzed, the most frequent malignancy was breast cancer [25%]. The first immunomodulator given after inclusion was a conventional immunosuppressant in 27% of patients, anti-TNF in 21%, or vedolizumab in 9%. With a median (interquartile range [IQR]) follow-up duration of 55 [23-100] months, 100 incident cancers were observed. Crude cancer incidence rates per 1000 person-years were 47.0 for patients receiving no immunomodulator, 36.6 in the anti-TNF cohort, and 33.6 in the vedolizumab cohort [p = 0.23]. Incident-cancer free survival rates were not different between patients receiving anti-TNF and those receiving vedolizumab [p = 0.56]. After adjustment, incidence rates were not different between patients receiving no immunomodulator, anti-TNF, or vedolizumab. Conclusions In this large multicentre cohort study, there was no difference of cancer incidence in those IBD patients with prior non-digestive malignancy, treated with vedolizumab or anti-TNF.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Date de dépôt :
2024-01-12T01:34:56Z
2024-03-26T09:52:29Z
2024-04-23T11:15:37Z
2024-03-26T09:52:29Z
2024-04-23T11:15:37Z